Trials / Completed
CompletedNCT05024994
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
A Phase II Clinical Trial of E7820 for Patients With Relapsed/Refractory Myeloid Malignancies With Mutations in Splicing Factor Genes.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether E7820 is an effective treatment for people with relapsed/refractory myeloid cancers with mutations in splicing factor genes. Participants will have acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7820 | 100mg of E7820 QD |
Timeline
- Start date
- 2021-08-13
- Primary completion
- 2025-06-19
- Completion
- 2025-06-19
- First posted
- 2021-08-27
- Last updated
- 2025-06-22
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05024994. Inclusion in this directory is not an endorsement.